Elliot B Tapper1,2, Shengchen Hao3, Menghan Lin3, John N Mafi4,5, Heather McCurdy2, Neehar D Parikh1,2, Anna S Lok1,2. 1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI. 2. Veterans Affairs, Ann Arbor, MI. 3. University of Michigan, Ann Arbor, MI. 4. Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles, CA. 5. RAND Health, RAND Corporation, Santa Monica, CA.
Abstract
Cirrhosis is morbid and increasingly prevalent, yet the U.S. health care system lacks enough physicians and specialists to adequately manage patients with cirrhosis. Although advanced practice providers (APPs) can expand access to cirrhosis-related care, their impact on the quality of care remains unknown. We sought to determine the effect on care quality and outcomes for patients managed by APPs using a retrospective analysis of a nationally representative American commercial claims database (Optum), which included 389,257 unique adults with cirrhosis. We evaluated a complication of process measures (i.e., rates of hepatocellular carcinoma [HCC] screening, endoscopic varices screening, and use of rifaximin after hospitalization for hepatic encephalopathy) and outcomes (30-day readmissions and survival). Compared with patients without APP care, patients with APP care had higher rates of HCC screening (adjusted odds ratio [OR] 1.23, 95% confidence interval 1.19, 1.27), varices screening (OR 1.20 [1.13, 1.27]), use of rifaximin after a discharge for hepatic encephalopathy (OR 2.09 [1.80, 2.43]), and reduced risk of 30-day readmission (OR 0.68 [0.66, 0.70]). Gastroenterology/hepatology consultation was also associated with improved quality metric performance compared with primary care; however, shared visits between gastroenterologists/hepatologists and APPs were associated with the best performance and lower 30-day readmissions compared with subspecialty consultation without an APP (OR 0.91 [0.87, 0.95]. Multivariate analysis adjusting for comorbidities, liver disease severity, and other factors including gastroenterology/hepatology consultation showed that patients seen by APPs were more likely to receive consistent HCC and varices screening over time, less likely to experience 30-day readmissions, and had lower mortality (adjusted hazard ratio 0.57, 95% confidence interval 0.55, 0.60). Conclusion: APPs, particularly when working with gastroenterologists/hepatologists, are associated with improved quality of care and outcomes for patients with cirrhosis.
Cirrhosis is morbid and increasingly prevalent, yet the U.S. health care system lacks enough physicians and specialists to adequately manage patients with cirrhosis. Although advanced practice providers (APPs) can expand access to cirrhosis-related care, their impact on the quality of care remains unknown. We sought to determine the effect on care quality and outcomes for patients managed by APPs using a retrospective analysis of a nationally representative American commercial claims database (Optum), which included 389,257 unique adults with cirrhosis. We evaluated a complication of process measures (i.e., rates of hepatocellular carcinoma [HCC] screening, endoscopic varices screening, and use of rifaximin after hospitalization for hepatic encephalopathy) and outcomes (30-day readmissions and survival). Compared with patients without APP care, patients with APP care had higher rates of HCC screening (adjusted odds ratio [OR] 1.23, 95% confidence interval 1.19, 1.27), varices screening (OR 1.20 [1.13, 1.27]), use of rifaximin after a discharge for hepatic encephalopathy (OR 2.09 [1.80, 2.43]), and reduced risk of 30-day readmission (OR 0.68 [0.66, 0.70]). Gastroenterology/hepatology consultation was also associated with improved quality metric performance compared with primary care; however, shared visits between gastroenterologists/hepatologists and APPs were associated with the best performance and lower 30-day readmissions compared with subspecialty consultation without an APP (OR 0.91 [0.87, 0.95]. Multivariate analysis adjusting for comorbidities, liver disease severity, and other factors including gastroenterology/hepatology consultation showed that patients seen by APPs were more likely to receive consistent HCC and varices screening over time, less likely to experience 30-day readmissions, and had lower mortality (adjusted hazard ratio 0.57, 95% confidence interval 0.55, 0.60). Conclusion: APPs, particularly when working with gastroenterologists/hepatologists, are associated with improved quality of care and outcomes for patients with cirrhosis.
Authors: Miguel R Arguedas; Gustavo R Heudebert; Mohamad A Eloubeidi; Gary A Abrams; Michael B Fallon Journal: Am J Gastroenterol Date: 2002-09 Impact factor: 10.864
Authors: Fasiha Kanwal; Tuyen Hoang; Jennifer R Kramer; Steven M Asch; Matthew Bidwell Goetz; Angelique Zeringue; Peter Richardson; Hashem B El-Serag Journal: Gastroenterology Date: 2010-12-22 Impact factor: 22.682
Authors: Amit G Singal; Sahil Mittal; Olutola A Yerokun; Chul Ahn; Jorge A Marrero; Adam C Yopp; Neehar D Parikh; Steve J Scaglione Journal: Am J Med Date: 2017-02-14 Impact factor: 4.965
Authors: Ira B Wilson; Bruce E Landon; Lisa R Hirschhorn; Keith McInnes; Lin Ding; Peter V Marsden; Paul D Cleary Journal: Ann Intern Med Date: 2005-11-15 Impact factor: 25.391
Authors: L Blue; E Lang; J J McMurray; A P Davie; T A McDonagh; D R Murdoch; M C Petrie; E Connolly; J Norrie; C E Round; I Ford; C E Morrison Journal: BMJ Date: 2001-09-29
Authors: Jasmohan S Bajaj; James B Wade; Douglas P Gibson; Douglas M Heuman; Leroy R Thacker; Richard K Sterling; R Todd Stravitz; Velimir Luketic; Michael Fuchs; Melanie B White; Debulon E Bell; HoChong Gilles; Katherine Morton; Nicole Noble; Puneet Puri; Arun J Sanyal Journal: Am J Gastroenterol Date: 2011-05-10 Impact factor: 10.864
Authors: Jessica A Davila; Louise Henderson; Jennifer R Kramer; Fasiha Kanwal; Peter A Richardson; Zhigang Duan; Hashem B El-Serag Journal: Ann Intern Med Date: 2011-01-18 Impact factor: 25.391
Authors: Lindsay Yoder; Andrea Mladenovic; Francis Pike; Raj Vuppalanchi; Haleigh Hanson; Laura Corbito; Archita P Desai; Naga Chalasani; Eric S Orman Journal: Am J Med Date: 2021-10-14 Impact factor: 4.965
Authors: Michelle Carbonneau; Tracy Davyduke; Stephen E Congly; Mang M Ma; Kim Newnham; Vanessa Den Heyer; Puneeta Tandon; Juan G Abraldes Journal: Can Liver J Date: 2021-02-24
Authors: Jeremy Louissaint; Katie Grzyb; Linda Bashaw; Rima A Mohammad; Neehar D Parikh; Elliot B Tapper Journal: Am J Gastroenterol Date: 2022-03-01 Impact factor: 12.045
Authors: Bandar Al-Judaibi; M Katherine Dokus; Waleed Al-Hamoudi; Dieter Broering; Mohammad Mawardi; Nasser AlMasri; Mohammed Aljawad; Ibrahim H Altraif; Faisal Abaalkhail; Saleh A Alqahtani Journal: Saudi J Gastroenterol Date: 2022 Mar-Apr Impact factor: 2.485
Authors: Nicole J Kim; Karine Rozenberg-Ben-Dror; David A Jacob; Nicole E Rich; Amit G Singal; Elizabeth S Aby; Ju Dong Yang; Veronica Nguyen; Anjana Pillai; Michael Fuchs; Andrew M Moon; Hersh Shroff; Parul D Agarwal; Ponni Perumalswami; Shaun Chandna; Kali Zhou; Yuval A Patel; Nyan L Latt; Robert Wong; Andres Duarte-Rojo; Christina C Lindenmeyer; Catherine Frenette; Jin Ge; Neil Mehta; Francis Yao; Jihane N Benhammou; Patricia P Bloom; Michael Leise; Hyun-Seok Kim; Cynthia Levy; Abbey Barnard; Mandana Khalili; George N Ioannou Journal: Clin Gastroenterol Hepatol Date: 2020-09-12 Impact factor: 11.382